Cargando…
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
BACKGROUND: The aim of this study is to determine whether immunohistochemical (IHC) assessment of Ki67 and p53 improves prognostication of oestrogen receptor-positive (ER+) breast cancer after breast-conserving therapy (BCT). In all, 498 patients with invasive breast cancer from a randomised trial o...
Autores principales: | Millar, E K A, Graham, P H, McNeil, C M, Browne, L, O'Toole, S A, Boulghourjian, A, Kearsley, J H, Papadatos, G, Delaney, G, Fox, C, Nasser, E, Capp, A, Sutherland, R L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142808/ https://www.ncbi.nlm.nih.gov/pubmed/21712826 http://dx.doi.org/10.1038/bjc.2011.228 |
Ejemplares similares
-
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012) -
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005) -
BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
por: Millar, E K A, et al.
Publicado: (2009) -
Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma
por: Wangsa, D, et al.
Publicado: (2008) -
Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)